Acid ceramidase is upregulated in AML and represents a novel therapeutic target

ECU Author/Contributor (non-ECU co-authors, if there are any, appear on document)
Su-Fern,Liu,Xin,Fox,Todd E.,Barth,Brian M.,Sharma,Arati,Turner,Stephen D.,A Tan (Creator)
East Carolina University (ECU )
Web Site:

Abstract: There is an urgent unmet need for new therapeutics in acute myeloid leukemia (AML) as standard therapy has not changed in the past three decades and outcome remains poor for most patients. Sphingolipid dysregulation through decreased ceramide levels and elevated sphingosine 1-phosphate (S1P) promotes cancer cell growth and survival. Acid ceramidase (AC) catalyzes ceramide breakdown to sphingosine, the precursor for S1P. We report for the first time that AC is required for AML blast survival. Transcriptome analysis and enzymatic assay show that primary AML cells have high levels of AC expression and activity. Treatment of patient samples and cell lines with AC inhibitor LCL204 reduced viability and induced apoptosis. AC overexpression increased the expression of anti-apoptotic Mcl-1, significantly increased S1P and decreased ceramide. Conversely, LCL204 induced ceramide accumulation and decreased Mcl-1 through post-translational mechanisms. LCL204 treatment significantly increased overall survival of C57BL/6 mice engrafted with leukemic C1498 cells and significantly decreased leukemic burden in NSG mice engrafted with primary human AML cells. Collectively, these studies demonstrate that AC plays a critical role in AML survival through regulation of both sphingolipid levels and Mcl-1. We propose that AC warrants further exploration as a novel therapeutic target in AML.

Additional Information

Language: English
Date: 2016

Email this document to

This item references:

TitleLocation & LinkType of Relationship
Acid ceramidase is upregulated in AML and represents a novel therapeutic target described resource references, cites, or otherwise points to the related resource.